ANL HealthcareBeta data

Adlai Nortye Group Ltd.

$9.58+2.24%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Singapore
Market cap: 616.9M USD
Enterprise value: 410.8M USD
Full-time employees: 109

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.10 vs a peer median of 0.63)bigger price swings (beta 1.10 vs peers 0.63)
Not enough data: growth

Would rank #1,009 of 1,157 fully scored healthcare companies (bottom 13%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 31% of revenue in 2025.
Adlai Nortye paid employees $2M in stock in 2025, 31% of its $5M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Not profitable yet. Reported a loss over the last 12 months.
Adlai Nortye reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

StockQuotient Score

28/ 100

Oct 5 28 → Nov 4 28

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

0/100

Weak

2/3 inputs reported · Partial data

Since last year: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-6.9%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-5.3%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield34.8%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

1/100

Weak

2/3 inputs reported · Partial data

Since last year: No major change

Why

Weaker than most peers on:

▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-714.0%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -59.24Sector median: 0.0706 · MAD: 0.1217

Return on assets-103.2%

SEC filings (IFRS mapped) · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capitalUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin100.0%

Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-20.2%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.10

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.41Sector median: 0.6250 · MAD: 0.3380

Current ratio9.55×

Yahoo FinanceReported value33% base weight · Z-score 5.03Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.12×

Yahoo FinanceReported value33% base weight · Z-score 0.48Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Adlai Nortye

Is Adlai Nortye getting weaker?: Its latest SEC filing (Apr 10, 2026) showed no major changes. Its overall score is unchanged at 28/100 since Oct 28, 2026.
How is Adlai Nortye valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -6.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.9% vs peers 1.5% (weaker than 100% of peers).
Is Adlai Nortye growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Adlai Nortye?: Less profitable than most of its peers. Profitability scores 1/100 against 1,393 healthcare peers. Return on assets -103.2% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -103.2% vs peers 1.7% (weaker than 100% of peers).
How risky is Adlai Nortye?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 9.55× vs a peer median of 2.59× (stronger than 87% of peers).Current ratio 9.55× vs peers 2.59× (stronger than 87% of peers). Beta 1.10 vs a peer median of 0.63 (weaker than 76% of peers).Beta 1.10 vs peers 0.63 (weaker than 76% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Dec 31, 2025 · filed Apr 10, 2026 · compared with the year ended Dec 31, 2023

No major changes

Worth watching: Adlai Nortye is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous year	Latest year	Change
Revenue (12 months)	5.0M USD	5.0M USD	0.0%
Net income (12 months)	−51.9M USD	−35.5M USD	−31.5%
Operating margin	-1058.6%	-714.0%	+344.6 pts
Free cash flow (12 months)	−52.0M USD	−33.6M USD	−35.3%
Cash	60.9M USD	8.1M USD	−86.8%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-18.9%	—	-1451.0%	—	-714.0%	—
Net margin	-124.0%	—	-2184.6%	—	-710.6%	—
Return on assets (ROA)	—	-81.0%	-83.9%	-72.8%	-103.2%	▼ 30 pts
Return on equity (ROE)	—	—	-145.5%	-203.5%	—	—
Free cash flow margin	-8.9%	—	-1137.0%	—	-672.8%	—
Current ratio	—	0.21×	2.04×	1.41×	0.65×	▼ 54%
Debt to equity	—	—	0.40×	1.03×	—	—
Interest coverage	-6.47×	-155.36×	-91.72×	-27.23×	-23.32×	▲ 14%

ANL price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.10 vs a peer median of 0.63)bigger price swings (beta 1.10 vs peers 0.63)

Not enough data: growth

Would rank #1,009 of 1,157 fully scored healthcare companies (bottom 13%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 31% of revenue in 2025.

Adlai Nortye paid employees $2M in stock in 2025, 31% of its $5M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Not profitable yet. Reported a loss over the last 12 months.

Adlai Nortye reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Questions investors ask about Adlai Nortye

Is Adlai Nortye getting weaker?

Its latest SEC filing (Apr 10, 2026) showed no major changes. Its overall score is unchanged at 28/100 since Oct 28, 2026.

How is Adlai Nortye valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -6.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.9% vs peers 1.5% (weaker than 100% of peers).

Is Adlai Nortye growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Adlai Nortye?

Less profitable than most of its peers. Profitability scores 1/100 against 1,393 healthcare peers. Return on assets -103.2% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -103.2% vs peers 1.7% (weaker than 100% of peers).

How risky is Adlai Nortye?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 9.55× vs a peer median of 2.59× (stronger than 87% of peers).Current ratio 9.55× vs peers 2.59× (stronger than 87% of peers). Beta 1.10 vs a peer median of 0.63 (weaker than 76% of peers).Beta 1.10 vs peers 0.63 (weaker than 76% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Revenue (12 months)

5.0M USD

5.0M USD

0.0%

Net income (12 months)

−51.9M USD

−35.5M USD

−31.5%

Operating margin

-1058.6%

-714.0%

+344.6 pts

Free cash flow (12 months)

−52.0M USD

−33.6M USD

−35.3%

Cash

60.9M USD

8.1M USD

−86.8%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-18.9%

—

-1451.0%

—

-714.0%

—

Net margin

-124.0%

—

-2184.6%

—

-710.6%

—

Return on assets (ROA)

—

-81.0%

-83.9%

-72.8%

-103.2%

▼ 30 pts

Return on equity (ROE)

—

-145.5%

-203.5%

—

Free cash flow margin

-8.9%

—

-1137.0%

—

-672.8%

—

Current ratio

—

0.21×

2.04×

1.41×

0.65×

▼ 54%

Debt to equity

—

0.40×

1.03×

—

Interest coverage

-6.47×

-155.36×

-91.72×

-27.23×

-23.32×

▲ 14%